Nalpain (Nalbuphine Hydrochloride)

Nalbuphine, the active ingredient in Nalpain, is an opioid analgesic presented as a sterile injectable solution for intramuscular, intravenous, and subcutaneous use. It is employed to manage moderate to severe pain in adult patients when other analgesics are insufficient.

GNH USA supplies Nalpain as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nalpain (nalbuphine) is used within the opioid analgesic pathway to treat various acute pain conditions.

- Postoperative pain: provides effective relief after surgical procedures. - Acute trauma pain: reduces pain intensity following injuries such as fractures or burns. - Labor pain: offers analgesia during childbirth while maintaining maternal safety.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness: feeling light‑headed or unsteady. - Nausea: sensation of needing to vomit. - Vomiting: expulsion of stomach contents. - Sedation: increased drowsiness or sleepiness. - Sweating: excessive perspiration. - Headache: mild to moderate cranial pain.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing requiring monitoring. - Hypotension: significant drop in blood pressure. - Urinary retention: difficulty emptying the bladder. - Allergic reactions: rash, itching, or anaphylaxis. - Seizures: rare convulsive episodes.

When using Nalpain, clinicians should observe several safety measures.

- Respiratory monitoring: assess breathing function regularly. - Sedation assessment: watch for excessive drowsiness. - Head injury caution: avoid in patients with increased intracranial pressure. - Discontinuation: taper gradually to prevent withdrawal. - Hepatic impairment: consider dose adjustment in liver disease. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Nalpain may interact with other medications, influencing its safety and efficacy.

Major Interactions (Avoid): - CNS depressants: concurrent use with benzodiazepines or barbiturates can enhance sedation. - MAO inhibitors: may precipitate severe hypertension or serotonin syndrome. - Other opioids: additive respiratory depression risk. - Alcohol: increases central nervous system depression. - CYP3A4 inhibitors: can raise nalbuphine plasma levels.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers: may reduce drug effectiveness. - Antihistamines: may augment sedation. - Antidepressants: monitor for enhanced CNS effects. - Diuretics: watch for electrolyte shifts. - Antihypertensives: possible additive hypotensive effect.